The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia.

@article{Griffiths2007TheUO,
  title={The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia.},
  author={Stephen D. Griffiths and John Burthem and Richard D. Unwin and Tessa L Holyoake and Junia V. Melo and G Marcelino E S Lucas and Anthony D. Whetton},
  journal={Molecular biotechnology},
  year={2007},
  volume={36 2},
  pages={81-9}
}
Chronic Myeloid Leukemia (CML) is a hematopoietic stem cell disease, associated with a t(9, 22) chromosomal translocation leading to formation of the BCR/ABL chimeric protein, which has an intrinsic tyrosine kinase activity. Recently, the BCR/ABL tyrosine kinase inhibitor imatinib mesylate (imatinib) has been successfully used clinically, although, disease relapse can still occur. The precise detail of the mechanism by which CML cells respond to imatinib is still unclear. We therefore… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Adipose-Derived Stem Cells

Methods in Molecular Biology • 2011
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…